Levothyroxine SSP extended until April 1

The serious shortage protocol for Levothyroxine 12.5mcg tablets has been extended until April 1, the Department of Health and Social Care has announced.

The SSP was due to expire today and the PSNC urged pharmacists to “exercise their professional judgement” when deciding if the “alternative product is suitable for the patient.”

“(The SSP) provides that for every two Levothyroxine 12.5 mcg tablets originally prescribed, one Levothyroxine 25 microgram tablet must be supplied with the dosage amended to one 25mcg tablet to be taken on alternate days,” the PSNC said.

Meanwhile, the negotiator said voriconazole 40mg/ml powder for oral suspension will be out of stock “until late April 2021” although 50mg, 100mg and 200mg tablets are available.

“Patients in primary care with insufficient supply who need continued treatment should be referred back to secondary care for review,” the PSNC said, adding that “unlicensed supplies of voriconazole 40mg/ml oral suspension can be sourced through Durbin PLC, Mawdsley’s Unlicensed, Smartway Pharma and UL Global Pharma.

Pioglitazone 15mg/metformin 850mg tablets (Competact) are also out of stock until early May.

Latest discussions

  1. Pre reg exams

    Thanks for your comments both - Richard ...

  2. Pre reg exams

    Having been qualified just over 40 years...

This website is for healthcare professionals, people who work in pharmacy and pharmacy students. By clicking into any content, you confirm this describes you and that you agree to Pharmacy Magazine's Terms of Use and Privacy Policy.

We use essential, performance, functional and advertising cookies to give you a better web experience. Find out how to manage these cookies here. We also use Interest Based Advertising Cookies to display relevant advertisements on this and other websites based on your viewing behaviour. By clicking "Accept" you agree to the use of these Cookies and our Cookie Policy.